Media Thread, page-11929

First 11929 Last

Share
Profile

Follow
Yamaha333

171 Posts.

76

19/02/24

13:52

Post #: 72484154
Share

Originally posted by Jov88: ↑

Thanks, Rainman.

It makes sense to listen when our CEO says Azer-Cel is being prioritised as the front runner. Assuming all goes well with Phase 1b we’ll be in a good position for BP to pounce.

The ideal scenario, a couple of big announcements get the IMUODs in the money. Significant cash injection if that happens would mean we almost wouldn’t need to raise again for current trials (not accounting for R&D grants). IMUODs would get IMU to around Q2 2026. ***IMUOEs expire at the end of August 2026 but could already have brought in funds for those wanting to start 12-month CGT timeline. It’s ambitious but also I’d imagine management wouldve be working on things so they align here.

Ideally, if IMUODs come in it’d still make sense to see a raise on the back of decent results; from either Azer-Cel, CF33, to cornerstone US based BP/Insto’s. Regardless of what people say about listing in the US, that’s where the big money is. If IMU has world leading tech, they need to be playing in a world leading pool of capital. Sorry to say, Australia just doesn’t cut it right now.My thoughts are similar to yours in so far as any success we see in CF33 could almost count double for future OnCARlytics results. However, im not as convinced the biggest inflection points for IMU this year won’t still come from Azel-Cel and CF33. This is purely based on patients treated. We’d have 1b data back and registrational trial confirmation for Azer-Cel and CF33 a fair few patients of the higher cohorts dosed. OnCARlytics combo doesn’t look like it will start dosing for a few months and at that how many patients would need to be dosed and data cleaned to see material benefit?! Of course if the response rates are ridiculously good on the few patients dosed then that’d change things.

Personally, for this year im hoping to see strong confirmation of efficacy in higher cohorts for CF33, confirmation that onCARlytics is getting tumours to express CD19 and Azer-Cel getting the nod for it’s registration study. That’s not too much to ask for!

Expand

interesting Jov you make no mention of our most advanced drug Her-vaxx ?

I have a sneaky suspicion that it will be licensed or even sold, though the company says it’s not a priority. Worldwide patents, proof of concept and overall outstanding survival rate , surely it’s close ?

IMU Price at posting: 10.8¢ Sentiment: Hold Disclosure: Held
14 Upvote

1 Great analysis

Reply

Top Stories

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

RNU

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

TX3

Canadian fieldwork yields multiple pegmatites for Trinex

AUG

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

There are more pages in this discussion • 2,695 more messages in this thread...

First 11929 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.3¢		Change -0.002(2.78%)		Mkt cap ! $389.5M

Open	High	Low	Value	Volume
5.5¢	5.6¢	5.3¢	$437.6K	8.128M

Buyers (Bids)

No.	Vol.	Price($)
28	1976114	5.2¢

Sellers (Offers)

Price($)	Vol.	No.
5.3¢	532869	17

View Market Depth

No.	Vol.	Price($)
28	1976114	0.052
19	3590220	0.051
40	3498278	0.050
37	5231001	0.049
20	1620835	0.048

Price($)	Vol.	No.
0.053	532869	17
0.054	573643	11
0.055	2102953	8
0.056	1370041	11
0.057	1299298	8

Last trade - 14.46pm 11/07/2024 (20 minute delay)

IMU (ASX) Chart

Media Thread, page-11929

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Canadian fieldwork yields multiple pegmatites for Trinex

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Media Thread, page-11929

Top Stories

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Canadian fieldwork yields multiple pegmatites for Trinex

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News